Cvrx, INC Form 4 insider transactions

Director Kirk G. Nielsen reports acquiring additional shares of CVRx, Inc. common stock through a series of purchases between May 12 and May 14, 2025.

Director Mudit K. Jain of CVRx, Inc. reports purchasing common stock in multiple transactions on May 12 and May 13, 2025.

CVRx's CEO, Kevin Hykes, purchased 5,000 shares of the company's common stock at a price of $4.84 per share on May 12, 2025.

Paul Verrastro, Chief Marketing & Strategy Officer of CVRx, Inc., reports acquiring 16,000 shares of common stock and options to purchase 24,000 shares.

CEO Kevin Hykes reports acquiring and disposing of CVRx, Inc. shares and stock options on February 28, 2025.

Chief Revenue Officer John Robert Allen reports acquiring 55,000 shares of common stock and 38,000 stock options in CVRx, Inc. on February 28, 2025.

CVRx's Chief Financial Officer, Jared Oasheim, reported acquiring 22,000 shares of common stock and 33,000 stock options on February 28, 2025.

Philip B. Adamson, Chief Medical Officer of CVRx, Inc., reports the acquisition of 20,000 shares of common stock and options to purchase 30,000 shares.

CVRx's Chief Marketing and Strategy Officer, Paul Verrastro, engaged in multiple stock transactions, including exercising options and selling shares, on November 19 and 21, 2024.

Director Kevin J. Ballinger reported the acquisition of stock options in CVRx, Inc. on September 3, 2024.

Director Mitch C. Hill acquired stock options for 36,136 shares of CVRx, Inc. on September 3, 2024.

Director Joseph P. Slattery of CVRx, Inc. purchased 3,000 shares of common stock at $8.10 per share on August 15, 2024, increasing his total holdings to 30,645 shares.

Director Joseph P. Slattery of CVRx, Inc. (CVRX) acquired 3,000 shares of common stock at $8.2386 per share on August 8, 2024, increasing his total holdings to 27,645 shares.

Director Joseph P. Slattery of CVRx, Inc. reports purchasing 2,500 shares of common stock at $9.09 per share on August 6, 2024, increasing his total holdings to 24,645 shares.

CVRx's CEO, Kevin Hykes, recently purchased 30,000 shares of CVRx stock at an average price of $8.3589 per share.

CVRx, Inc. CEO Kevin Hykes reports the acquisition of 180,000 stock options in a recent Form 4 filing with the SEC.

John Robert Allen, Chief Revenue Officer of CVRx, Inc., reports the acquisition of stock options.

An amended SEC filing reveals a correction to a previous report, clarifying the number of stock options held by CVRx director Ali Behbahani.

An amended SEC filing reveals a correction to a previous Form 4, addressing an understatement of stock options granted to CVRx director Kirk G. Nielsen.

Joseph P. Slattery, a director of CVRx, Inc., filed an amended Form 4 to correct an understatement of stock options granted.

Mudit K. Jain, a director of CVRx, Inc., filed an amended Form 4 to correct an understatement of stock options granted in a previous filing.

Martha Shadan, a director of CVRx, Inc., filed an amended Form 4 to correct an understatement of stock options granted.

Director Ali Behbahani acquired stock options in CVRx, Inc. on June 4, 2024.

Director Joseph P. Slattery acquired 20,961 stock options in CVRx, Inc. on June 4, 2024.

Director Mudit K. Jain acquired stock options in CVRx, Inc. on June 4, 2024.

Director Martha Shadan acquired 20,961 stock options in CVRx, Inc. on June 4, 2024.

Director Kirk G. Nielsen acquired 20,961 stock options in CVRx, Inc. on June 4, 2024.

CVRx's SVP of U.S. Sales, Palmer Craig E., reported exercising stock options at a price of $0.237 on March 25, 2024, resulting in the acquisition and disposal of common stock.

Johnson & Johnson reports transactions involving CVRx, Inc. common stock and derivative securities, including warrant exercises and stock option acquisitions, through its subsidiary Johnson & Johnson Innovation JJDC, Inc.

Paul Verrastro, Chief Marketing & Strategy Officer at CVRx, Inc., reported a gift transaction involving the company's common stock on February 23, 2024.